Drug Patents Expiring in 2044
1. Artesunate patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12121506 | AMIVAS | Artesunate powders, pharmaceutical compositions and methods of manufacture |
Feb, 2044
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2025 |
| Orphan Drug Exclusivity(ODE-290) | May 26, 2027 |
Drugs and Companies using ARTESUNATE ingredient
NCE-1 date: 26 May, 2024
Market Authorisation Date: 26 May, 2020
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARTESUNATE family patents
2. Exparel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12156940 | PACIRA PHARMS INC | Manufacturing of bupivacaine multivesicular liposomes |
Jul, 2044
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 28, 2014 |
| New Indication(I-771) | Apr 06, 2021 |
| New Patient Population(NPP) | Mar 22, 2024 |
| New Indication(I-929) | Nov 09, 2026 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 28 October, 2011
Treatment: NA
Dosage: INJECTABLE, LIPOSOMAL
How can I launch a generic of EXPAREL before it's drug patent expiration?
More Information on Dosage
EXPAREL family patents